Over the past month, nearly every maker of SSRI and similar antidepressant drugs have added extensive warnings to their labels. These new warnings inform users of the risk of post-partum hemorrhaging if taken in the month prior to given birth. Because depression often occurs during pregnancy and antidepressants are commonly prescribed to women who suffer from pre-partum depression, these new warnings could lead to a significant mass tort litigation.
Attorney Michael Lynch of the Michael Brady Lynch Firm and John Ray of The Ray Group will provide information and our opinions of the potential litigation against most if not all makers of antidepressant drugs.
At this point, we are still investigating what led to the new warnings added to most antidepressant drugs. We are not yet certain whether this is a case you should consider being involved in, but we will have more information to provide at our September 22nd- 24th litigation conference in Fort Lauderdale. The new warnings seem to warn of the risk of post-partum hemorrhaging while at the same time downplaying the risk. It is important to know that the word hemorrhage is not just another word for bleeding, the word hemorrhage generally denotes a life-threatening bleeding event. This would indicate that even if the numerical per user risk is low, those who do experience a hemorrhage are likely to suffer severe injury or death.
Considering the broad prescribing of antidepressants to pregnant women, even if the number of women as a percentage of users is low, the total number of potential plaintiffs could be significant. We will update you at the September 22nd-24th conference in Fort Lauderdale. If we find that this is litigation your firm should consider participating in, we will provide all the details at the conference. This will probably be a “go big” or don’t go at all proposition.
The new warning is significant, and we believe that failure to warn claims would have merit, the only question we are trying to resolve is whether the potential plaintiff numerosity is sufficient to make marketing for these cases practical. The more we research this metric the more we are coming to believe that the potential plaintiff numerosity might be more than sufficient. The litigation update conference is being held at the Riverside Hotel in Fort Lauderdale, September 22-24th. Register and book your room today to get information on all current and emerging mass tort cases your firm should be part of now and in the immediate future.
Book your room today: http://bookings.ihotelier.com/bookings.jsp?groupID=3956304&hotelID=15542
This is a standardised guide to give you an idea of what size you will need, however some brands may vary from these conversions.
Ready to Wear Clothing
Size | XXS - XS | XS - S | S - M | M - L | L - XL | XL - XXL |
---|---|---|---|---|---|---|
UK | 6 | 8 | 10 | 12 | 14 | 16 |
US | 2 | 4 | 6 | 8 | 10 | 12 |
Italy (IT) | 38 | 40 | 42 | 44 | 46 | 48 |
France (FR/EU) | 34 | 36 | 38 | 40 | 42 | 44 |
Denmark | 32 | 34 | 36 | 38 | 40 | 42 |
Russia | 40 | 42 | 44 | 46 | 48 | 50 |
Germany | 32 | 34 | 36 | 38 | 40 | 42 |
Japan | 5 | 7 | 9 | 11 | 13 | 15 |
Australia | 6 | 8 | 10 | 12 | 14 | 16 |
Korea | 33 | 44 | 55 | 66 | 77 | 88 |
China | 160/84 | 165/86 | 170/88 | 175/90 | 180/92 | 185/94 |
Jeans | 24-25 | 26-27 | 27-28 | 29-30 | 31-32 | 32-33 |
Color: Gray
1 X $113.88
Comments (3)